** NEWS**
Just breaking.... Amgen has revived the old Synergen project and plans to file for RA. The combination of TNF antagonism (Celltech, Chiron, Bayer, and the major players, IMNX and CNTO) and IL-1ra could then be used off-label for sepsis. If BPI21 gets the nod, then there is the possibility that an effective cocktail, albeit a disgustingly expensive one, will be available for Gram-negatives. Throw in some work from Merck and a complement inhibitor or two, and you too, for only $40K, can have a cure for acute inflammation......
Monday July 12, 4:55 pm Eastern Time
Company Press Release
Amgen Announces 22% Increase in Second- Quarter
Earnings per Share, Plans FDA Filing of Potential
Rheumatoid Arthritis Treatment in 1999 and Raises
1999 Earnings Guidance
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--July 12, 1999--Amgen (Nasdaq:AMGN - news) today announced that
earnings per share for the second quarter ended June 30, 1999 increased 22 percent, to $0.50 from $0.41 for the second quarter a
year ago. Net income increased 24 percent, to $268 million from $216 million. Total product sales for the quarter increased 21
percent, to $738 million from $611 million.
Additionally, based on the strength of the results of two large phase 2 randomized and controlled studies in rheumatoid arthritis and
discussions with the Food and Drug Administration, the Company plans to file a BLA with the agency by the end of the year for
approval of IL-1ra. An additional phase 3 efficacy trial will not be needed for filing. (snip) |
